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Despite many beneficial outcomes of the conventional
enzyme replacement therapy (ERT), several limitations
such as the high-cost of the treatment and various
inadvertent side effects including the occurrence of an
immunological response against the infused enzyme and
development of resistance to enzymes persist. These issues
may limit the desired therapeutic outcomes of a majority
of the lysosomal storage diseases (LSDs). Furthermore,
the biodistribution of the recombinant enzymes into the
target cells within the central nervous system (CNS),
bone, cartilage, cornea, and heart still remain unresolved.
All these shortcomings necessitate the development of
more effective diagnosis and treatment modalities against
LSDs. Taken all, maximizing the therapeutic response with
minimal undesired side effects might be attainable by the
development of targeted enzyme delivery systems (EDSs)
as a promising alternative to the LSDs treatments, including
different types of mucopolysaccharidoses (MPSs) as well as
Fabry, Krabbe, Gaucher and Pompe diseases.

eplacing the defective enzymes with a recombinant
human enzyme in lysosomal storage diseases
(LSDs) and restoring the enzymatic activity was
first proposed by Christian de Duve in 1964.1 The LSDs, as
a heterogeneous group of disorders, are involved in various
genetic defects.2 They are a group of 50-60 genetically
inherited rare disorders, which are caused by the deficient
activity of a specific lysosomal enzyme and the gradual
accumulation of its non-degraded substrates, including
sphingolipids, carbohydrates, glycogen, glycoproteins, and
mucopolysaccharides.3 Lysosomal storage of substrates
leads to a number of complications such as metabolic
imbalances, widespread cellular dysfunction through cell
signaling, communication alteration, and disruption of
lipid rafts pathway, as well as downstream of autophagy
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processes.4 The LSDs patients during their early childhood
suffer from multifaceted clinical symptoms that can affect
their musculoskeletal system, lung, heart, liver, spleen, and
eyes. In addition, most LSDs patients have mild to severe
central nervous system (CNS) implications and they may
even die in the early years of life owing to cardiorespiratory
failures (Pompe disease).1
Various treatment strategies have been evaluated
against the LSDs, including gene therapy, small molecule
therapies, enzyme replacement therapy (ERT), lysosome
exocytosis, and organ/cell transplantation.5 Currently,
ERT and hematopoietic stem cell transplantation (HSCT)
have been advanced for the clinical trials, but due to the
complicated nature of the LSDs, none of these methods
addresses all aspects of the disease. Considering the
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effectiveness and limitations of each method when applied
alone, combination of ERT and any other therapy is
proposed in various studies to overcome these limitations.6
Up to now, several ERTs have been approved for the clinical
applications in Gaucher, Fabry, Krabbe, and Pompe
diseases, as well as different mucopolysaccharidoses MPSs
(e.g., MPS I, II, and IV) as lysosomal storage disorders
(Table 1).5 BioMarin Pharmaceutical Company is a global
leader in developing and commercializing innovative
biopharmaceuticals for the genetically derived rare
diseases. Aldurazyme®, Vimzim®, and Naglazyme®, as
recombinant human enzymes, have been produced by this
company for the treatment of MPS I, IV, VI, respectively.
The intravenous (IV) administrations of approved
enzymes in the LSDs generally represent significant
clinical benefits, including improved walking ability,
ameliorated respiration, and improved life-quality.7 The
LSDs require continuous treatment for optimal clinical
outcomes, therefore the cost-effectiveness and accessibility
to ERT should be considered as an essential point in the
treatment of these diseases. Despite the financial and
regulatory advantages for the “orphan drug” in the U. S.,
pharmaceutical industries have priced the LSDs therapy
products among the most expensive treatment modalities
in the market. Unfortunately, due to the high-cost of ERT
(usually over US$ 100 000/patient per year), they are
not often accessible for countries with fewer fundings.8
Besides, the major impediment to the development of
enzymes as drugs for the LSDs is the limited clinical trials
due to patients paucity in the population. Furthermore,
while performing pre-clinical studies in animal models
has been strongly recommended, in most cases, due to the
lack of such suitable animal models studies, the clinical
trials have been performed directly in human patients.9
Immune response and the IgG antibodies (Abs)
generation against the foreign infused enzymes is another
considerable issue of the ERT, which plays a pivotal role
in the patients' safety as well as efficacy and success of the

treatment. In fact, the neutralizing Abs can reduce the
efficacy of ERTs via direct interfering with the enzyme
activity (Figure 1). They can interact with the active site
of the enzyme and/or ligands involved in the binding
to a receptor on the target cells (mannose-6-phosphate
receptors for most LSDs, mannose and lysosomal integral
membrane protein 2 (Limp2) receptors for Gaucher
disease) that lead to blocking the cellular uptake and
lysosomal targeting of the enzyme.10 In addition, immune
reactions intensity appears to be dependent on the
presence or absence of residual mutant enzymes. Crossreactive immunologic materials (CRIM) status may be
predicted by genotyping for GAA gene in Pompe diseases,
and initial/early immunomodulation may induce
tolerance and result in an optimized therapy.7
Despite the therapeutic features of systemicallyadministered ERTs against LSDs, the biodistribution
of the enzymes into the difficult sites of pathology
(especially into CNS, bone, cartilage, cornea, and heart)
still remains as a striking challenge. Further, in the MPS,
the accumulation of glycosaminoglycans (GAGs) in the
cells and tissues all over the body result in devastating
widespread dysfunctions in different tissues and organs.
For instance, MPS manifestations in the eye include
both the anterior segments (cornea, conjunctiva) and
the posterior segments (retina, sclera, optic nerve).11 A
clear evidence demonstrates that approximately 75% of
LSDs patients with the neurological dysfunctions might
not be treated with the available ERTs.12 The bloodbrain barrier (BBB), as one of the main obstacles in the
confrontation with the enzyme biodistribution, presents
an impenetrable barrier between the bloodstream and the
CNS, by which controls the inward and outward traverse
of mostly hydrophilic enzymes utilized for the treatment
of the LSDs selectively (Figure 1).13,14 Further, as a result,
ERT often fails to provide the desired clinical outcomes,
in large part due to its non-specific biodistribution, low
bioavailability, and high degradation rate. Therefore,

Table 1. Approved enzyme replacement therapies available for the lysosomal storage disorders
LSDs

Deficient enzyme

Inheritance

FDA approved ERT and Brand name

MPS I (Hurler syn.)
MPS II (Hunter syn.)
MPS IV A (Morquio A syn.)
MPS VI (Marateaux-Lamy syn.)

α-L-iduronidase
Iduronate sulfatase
N-acetylgalactosamine 6-sulfatase
N-acetylgalactosamine 4-sulfatase

Autosomal
X-linked
Autosomal
Autosomal

Laronidase (Aldurazyme™)/ 2003-FDA, EMA
Idursulfase (Elaprase™)/ 2006-FDA; 2007-EMA
Elosulfase Alfa (Vimzim™)/ 2014-FDA
Galsulfase (Naglazyme™)/ 2005-FDA; 2006-EMA

Fabry disease

α-galactosidase

X-linked

Agalsidase α (Fabrazyme™)/ 2001-EMA
Agalsidase β (Replagal™)/ 2003-FDA, EMA

Pompe diseas

α-glucosidase

Autosomal

Aglucosidase (Myozyme™)/ 2006-FDA, EMA
Aglucosidase (Lumizyme™)/ 2010-FDA

Gaucher disease

β -glucocerebrosidase

Autosomal

Aglucerase (Ceredase™)/ 1991-FDA
Imiglucerase (Cerezyme™)/ 1994-FDA; 1997-EMA
Velaglucerase (VPRIV™)/ 2010-FDA, EMA
Taliglucerase (Elelyso™)/ 2012-FDA

Lysosomal acid lipase deficiency

Lysosomal acid lipase

Autosomal

Sebelipase α (Kanuma™)/ 2015-FDA,EMA

MPS: mucopolysaccharidosis; FDA: U.S. Food and Drug Administration; EMA: European Medical Agency.1,5,7
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Remaining challenges in the enzyme replacement therapy

Fig. 1. Schematic representation for the remaining challenges in the enzyme replacement therapy.

enhancing the therapeutic response by the development of
safe and efficient targeted enzyme delivery systems (EDSs)
may provide a promising alternative to the currently used
treatments in LSDs.15,16
Different methods have been developed to overcome the
limited access of enzymes into the difficult pathological
sites. Based on the receptor-mediated lysosomal enzyme
delivery system, it has been shown that increasing the
presence of M6P residues on the recombinant enzyme
or enhancing the expression rate of the M6PRs on the
target cells can improve the cellular uptake of the enzyme
through active targeting mechanism.17,18
In recent years, unprecedented attention has been
paid to the development of enzyme-loaded nanosystems
(ENSs) using advanced nanobiomaterials to enhance
the efficacy of ERT while minimizing the side effects.15
Different nanocarriers can be utilized for engineering of
nanoscaled EDSs, including biodegradable nanomicelles,
nanoliposomes, and polymer- and lipid-based
nanoparticles (Figure 1).19 Enzyme encapsulation can veil
the enzyme and its physicochemical characteristics, which
can eradicate some of the key limitations of ERT, including
undesired immunologic reactions and biodegradation. It
can also protect the recombinant enzymes from unwanted
biological impacts, non-selective biodistribution, and
improve the pharmacological response by increasing the
drug absorption, controlled-release of enzyme supply,
pharmacokinetics (PK), and pharmacodynamics (PD)
properties.20,21
Besides, targeted NSs such as polymeric/lipidic
nanoparticles, decorated with homing agents (e.g.,
aptamers or antibodies), can also be used in crossing the
biological barriers such as BBB and blood-ocular-barrier
(BOB). Thus, they are being considered as innovative and
effective approaches for the treatment of brain disorders.12

In addition, encapsulated-cell therapy (ECT) along with
another treatment strategy, has been considered as an
interesting combined therapy method for the treatment
of LSDs.22,23 One of the most pivotal advantages of ECT
is to cover engineered cells by biocompatible devices
that can be surgically implanted into different sites in
the host body, especially in difficult-to-access sites such
as the brain and eye to deliver constant amounts of the
enzyme for prolonged periods of time.13 In the case of the
eye, because of the efficient blockades provided by both
epithelial and endothelial cells,24,25 the targeted delivery
of drugs using advanced technologies and devices might
provide great clinical outcomes.19 For example, thermosresponsive sol-gel injectable hydrogels offer great
prospective applications in drug delivery, cell therapy and
tissue engineering.26 It should be noted that some of these
systems have mostly been used in the preclinical stages
and the clinical researches are essential for the approval of
their long-term safety and therapeutic outcomes.
Based on these findings, it is envisioned that the
currently used ERT modalities are not completely effective
for all types of LSDs. We envision that the ultimate therapy
of LSDs in the future would be based on the gene and/or
cell therapy. For example, in the case of Krabbe disease,
AAVrh10 gene therapy has been shown to ameliorates the
central and peripheral nervous system’s pathologies in
murine and canine models of this disease.27 At this point,
perhaps the main challenge in the treatment of LSDs is
to deliver therapeutic agents to the diseased cells/tissue
potentially using nanoscaled EDSs. Various multimodal
nanomedicines have previously been developed against
different types of diseases.28-42 Further, we know that
the size and morphology of NSs can influence the
pharmacokinetics and final fate of cargo drug molecules.43
Depending on the desired biological targets and impacts
BioImpacts, 2018, 8(3), 153-157
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of the ERTs, the use of passive and active targeting
mechanisms should be rationalized and fully addressed
in the EDSs. Nevertheless, development of targeted NSs
for enzyme delivery to CNS and other hard-to-reach
tissue is considered as the main challenge. Vesicular
trafficking mechanisms (e.g., clathrin-coated pits and
membranous caveolae) in the LSDs should also be fully
addressed. Lysosomal compartments, as acidic vesicular
machineries of the cells, encompass over 60 different
types of hydrolases and 50 membrane proteins and other
biological machineries are involved in degradation of
biological entities. We still need to understand the holistic
roles of the lysosomal membrane transporters involved in
the lysosomal trafficking.44 Interdigitating of lysosomal
compartments with other cellular organelles seems to
be largely dependent on the function of lysosomal ion
channels and transporters, dysregulation of which might
attribute to the pathogenesis of LSDs. We still need to
know the roles of cell membrane vesicular entities such as
lipid rafts and cytoplasmic macromolecules such as coat
proteins in the vesicular trafficking of the cells. Likewise,
to treat the LSDs, a number of issues in relevance to the
genetics and/or epigenetics of the lysosomal compartments
need to be understood. Taken all together, perhaps, it is the
time to change our research perspective from a restricted
outlook towards a holistic approach. To this end, we
need to understand the hallmarks of the LSDs and their
biochemical and clinical aspects to be able to improve
patients’ well-being with more effective treatments. In this
line, development of nanoscaled personalized medicines
against LSDs appears to be an inevitable endeavor.
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